Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinryze for acute antibody-mediated rejection in kidney transplant recipients
2015-000726-11Phase 3Terminated
- Sponsor
- Takeda
- Start
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Antibody-mediated kidney allograft rejection (AMR) and kidney allograft rejection comparing Cinryze plus background AMR therapy with Placebo plus background AMR therapy (2 arms). Primary endpoint: Proportion of subjects with new or worsening transplant glomerulopathy at 6 months. Started Sep 2015; status: terminated.
02
Drugs
c1-esterase inhibitor
03
Conditions
Antibody-mediated kidney allograft rejection (AMR)kidney allograft rejection
Beyond the preview
Go deeper on 2015-000726-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000726-11.